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Global, regional, and national disability-adjusted life years 
(DALYs) for 306 diseases and injuries and healthy life 
expectancy (HALE) for 188 countries, 1990–2013: quantifying 
the epidemiological transition
GBD 2013 DALYs and HALE Collaborators*
Summary 
Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data 
using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable 
comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate 
summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible 
comparative assessments of broad epidemiological patterns across countries and time. These summary measures can 
also be used to quantify the component of variation in epidemiology that is related to sociodemographic development.
Methods We used the published GBD 2013 data for age-speciﬁ c mortality, years of life lost due to premature mortality 
(YLLs), and years lived with disability (YLDs) to calculate DALYs and HALE for 1990, 1995, 2000, 2005, 2010, and 2013 
for 188 countries. We calculated HALE using the Sullivan method; 95% uncertainty intervals (UIs) represent 
uncertainty in age-speciﬁ c death rates and YLDs per person for each country, age, sex, and year. We estimated DALYs 
for 306 causes for each country as the sum of YLLs and YLDs; 95% UIs represent uncertainty in YLL and YLD rates. 
We quantiﬁ ed patterns of the epidemiological transition with a composite indicator of sociodemographic status, 
which we constructed from income per person, average years of schooling after age 15 years, and the total fertility rate 
and mean age of the population. We applied hierarchical regression to DALY rates by cause across countries to 
decompose variance related to the sociodemographic status variable, country, and time.
Findings Worldwide, from 1990 to 2013, life expectancy at birth rose by 6·2 years (95% UI 5·6–6·6), from 65·3 years 
(65·0–65·6) in 1990 to 71·5 years (71·0–71·9) in 2013, HALE at birth rose by 5·4 years (4·9–5·8), from 56·9 years 
(54·5–59·1) to 62·3 years (59·7–64·8), total DALYs fell by 3·6% (0·3–7·4), and age-standardised DALY rates per 
100 000 people fell by 26·7% (24·6–29·1). For communicable, maternal, neonatal, and nutritional disorders, global 
DALY numbers, crude rates, and age-standardised rates have all declined between 1990 and 2013, whereas for non-
communicable diseases, global DALYs have been increasing, DALY rates have remained nearly constant, and age-
standardised DALY rates declined during the same period. From 2005 to 2013, the number of DALYs increased for 
most speciﬁ c non-communicable diseases, including cardiovascular diseases and neoplasms, in addition to dengue, 
food-borne trematodes, and leishmaniasis; DALYs decreased for nearly all other causes. By 2013, the ﬁ ve leading 
causes of DALYs were ischaemic heart disease, lower respiratory infections, cerebrovascular disease, low back and 
neck pain, and road injuries. Sociodemographic status explained more than 50% of the variance between countries 
and over time for diarrhoea, lower respiratory infections, and other common infectious diseases; maternal disorders; 
neonatal disorders; nutritional deﬁ ciencies; other communicable, maternal, neonatal, and nutritional diseases; 
musculoskeletal disorders; and other non-communicable diseases. However, sociodemographic status explained less 
than 10% of the variance in DALY rates for cardiovascular diseases; chronic respiratory diseases; cirrhosis; diabetes, 
urogenital, blood, and endocrine diseases; unintentional injuries; and self-harm and interpersonal violence. 
Predictably, increased sociodemographic status was associated with a shift in burden from YLLs to YLDs, driven by 
declines in YLLs and increases in YLDs from musculoskeletal disorders, neurological disorders, and mental and 
substance use disorders. In most country-speciﬁ c estimates, the increase in life expectancy was greater than that in 
HALE. Leading causes of DALYs are highly variable across countries.
Interpretation Global health is improving. Population growth and ageing have driven up numbers of DALYs, but 
crude rates have remained relatively constant, showing that progress in health does not mean fewer demands on 
health systems. The notion of an epidemiological transition—in which increasing sociodemographic status brings 
structured change in disease burden—is useful, but there is tremendous variation in burden of disease that is not 
associated with sociodemographic status. This further underscores the need for country-speciﬁ c assessments of 
DALYs and HALE to appropriately inform health policy decisions and attendant actions.
Funding Bill & Melinda Gates Foundation.
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Introduction
The Global Burden of Disease study 2013 (GBD 2013) 
seeks to bring together all available epidemiological data 
using a coherent measurement framework, standardised 
estimation methods, and transparent data sources to 
allow comparisons of health loss to be made over time 
and across causes, age–sex groups, and geographies. 
The GBD 2013 data for disease and injury incidence and 
prevalence, years lived with disability (YLDs), causes of 
death, and years of life lost because of premature 
mortality (YLLs) for 188 countries provide an opportunity 
to assess the eﬀ ect of recent changes in population 
health by examining summary measures of health loss 
attributed to speciﬁ c causes, expressed in DALYs, and 
summary measures of average population health, 
expressed as HALE.1,2 These measures are crucial to 
track health progress, strengthen policy decisions, assess 
programme eﬀ ects and results, and inform health 
service and research priorities. Such holistic measures 
of population health, encompassing both disability and 
mortality levels and patterns in populations, are also 
attracting interest as part of the discussion around the 
Sustainable Development Goals .3–5
A hallmark of the GBD approach is an emphasis on 
making national data easier to compare by taking into 
account the extensive variation that exists in national 
medical certiﬁ cation and cause of death coding practices 
and widely varying case deﬁ nitions and measurement 
methods used to track the incidence and prevalence of 
diseases and injuries.1,2 The GBD not only provides 
detailed metrics for speciﬁ c causes, but also generates 
summary measures, such as DALYs and HALE, which 
enable comparative assessments of broad epidemiological 
patterns across countries and diﬀ erent time periods. 
HALE is a useful summary of overall health for a country 
and DALYs allow assessment of both premature mortality 
and non-fatal outcomes by cause. These broad summary 
measures allow quantiﬁ cation of general trends, such as 
the epidemiological transition, while also making clear 
how countries and regions deviate from general 
patterns.6–9 The unfolding of the HIV epidemic and the 
rise of adult mortality, especially among men in Eastern 
Europe and Central Asia, have called into question the 
notion of a universal pattern of epidemiological change 
that occurs with sociodemographic development.2,10–13 
However, the general notion of a shift from communicable 
to non-communicable causes of disease burden and 
injuries remains a powerful framework for global and 
regional health policy debates.9,14–18 The GBD provides an 
opportunity to quantify these patterns and explore the 
extent to which epidemiological change is driven by 
sociodemographic change, reduction of health risks, 
improvement of health management, or other local 
factors.
GBD 2013 results for deaths, YLLs, incidence, 
prevalence, and YLDs by cause for 1990 to 2013 for 
188 countries have already been published.1,2 In this study 
we use these GBD 2013 results to calculate DALYs and 
HALE. These summary metrics are used to characterise 
broad patterns of lost healthy life and cross-country 
Research in context
Evidence before this study
In 2012, results from the ﬁ rst complete revision of the Global 
Burden of Disease (GBD) since the ﬁ rst assessment in 1993 
became available. This eﬀ ort was called the GBD 2010 study and 
reported on disability-adjusted life-years (DALYs) and 
health-adjusted life expectancy (HALE) by country for 1990 and 
2010 based on analyses of an extensive data collection eﬀ ort to 
collate all available information on causes of death and disease 
occurrence in 187 countries. In response to the need for 
up-to-date information about the health of populations to 
inform health policy decision making, a decision was made to 
produce annual updates. The GBD 2013 is the ﬁ rst of these 
annual updates. In previous papers on the GBD 2013 study, we 
have documented the new data and new methods used to 
assess mortality and morbidity by country and over time.
Added value of this study
Here, we present the results for the aggregation of mortality 
and morbidity in terms of DALYs and HALE by country and for 
the time period 1990 to 2013. We examined to what extent the 
changes in DALYs since 1990 by disease and country can be 
explained by a composite indicator of sociodemographic status, 
constructed from income per person, years of schooling after 
age 15 years, median age of the population and total fertility 
rate. These GBD 2013 results for the period 1990 to 2013 for 
DALYs and HALE supersede all previously published GBD 
ﬁ ndings on DALYs and HALE.
Implications of all the available evidence
Numbers of DALYs and crude and age-standardised DALY rates 
for communicable diseases, maternal, neonatal, and nutritional 
disorders have decreased since 1990. For non-communicable 
diseases, the number of DALYs have increased, crude rates have 
remained stable, and age-standardised rates have decreased. 
Global health is improving but population increase and ageing 
are keeping the crude rates of DALYs constant, showing that 
progress in health does not mean fewer demands on health 
systems. The epidemiological transition, as quantiﬁ ed using our 
sociodemographic status indicator, accounts for much of the 
variation between countries and over time for most 
communicable, maternal, and neonatal causes but not for 
many non-communicable causes such as cardiovascular disease. 
The large variation in burden that is not associated with 
sociodemographic status emphasises the need for ongoing 
detailed assessments of DALYs and HALE at the country level to 
inform health policies.
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variations within these patterns. The GBD 2013 provides a 
complete re-analysis of each country’s data from 1990 to 
2013 and thus supersedes all previously published GBD 
analyses of DALYs and HALE.
Methods
Study design
GBD 2013 uses a hierarchy of causes that organises 
306 diseases and injuries into four levels of 
classiﬁ cation, the rationale for which has been 
described previously.2,19 The ﬁ rst level distinguishes 
three broad categories: ﬁ rst, communicable, maternal, 
neonatal, and nutritional disorders; second, non-
communicable diseases; and third, injuries. Level 2 has 
21 mutually exclusive and collectively exhaustive 
categories, level 3 has 163 categories, and level 4 has 
254 categories. The full cause list, including 
International Classiﬁ cation of Diseases tenth edition 
(ICD-10) codes, has been reported previously.1,2 
Mortality rates and causes of death for each country–
age–sex–year group have been estimated in accordance 
with some general principles: identiﬁ cation of all 
available data sources, evaluation of the quality and 
correction for known bias in each data source, 
consistent statistical estimation including uncertainty 
analysis, and cross-validation analysis to assess model 
performance. Details of data sources and estimation 
methods used to deal with missing data and multiple 
measurements for the same country–age–sex–year 
group have been described previously.2 Disease and 
injury incidence and prevalence and computation of 
YLDs have been estimated in line with similar 
principles of identiﬁ cation and assessment of 
the quality of all available sources for 2337 sequelae of 
the 301 diseases and injuries.1 The discrepancy between 
the 306 diseases and injuries for which DALYs are 
calculated and the 301 diseases and injuries for which 
YLDs are calculated is attributable to ﬁ ve diseases that 
cause death but do not cause disability: sudden infant 
death syndrome, indirect maternal deaths, late maternal 
deaths, maternal deaths aggravated by HIV/AIDS, and 
aortic aneurysm. Various statistical estimation methods 
were used depending on the details of speciﬁ c diseases, 
the most common approach being the application of a 
Bayesian metaregression model, DisMod-MR 2.0.20 We 
used alternative methods when the basic susceptible, 
with disease, and dead states in DisMod-MR 2.0 were 
insuﬃ  cient to capture the natural history of a sequela. 
We aggregated sequelae prevalence into YLDs ﬁ rst by 
estimating the distribution of comorbidities through 
microsimulation, and second by using disability 
weights derived from population-based surveys of the 
general public to assign disability weights to each 
sequela and combination of sequelae—details of both 
steps have been described previously.1,21
We used the GBD 2013 results for YLLs2 and YLDs1 to 
calculate DALYs. To calculate HALE, we used YLDs per 
Figure 1: Survivorship curve 
stratiﬁ ed by disability 
weight in 2013
Health survivorship function 
showing the fraction of a birth 
cohort alive at each age 
exposed to 2013 death rates, 
with the fraction of time spent 
at each age by the birth cohort 
decomposed by level of 
disability weight. Countries are 
grouped by socidemographic 
status into quintiles, including 
the lowest quintile (A), the 
three middle quintiles (B), and 
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person and life tables.1,2 We applied decomposition of 
variance using hierarchical regression to DALY rates by 
cause.
Years lived with disability
For each year for which YLDs have been estimated (1990, 
1995, 2000, 2005, 2010, and 2013), we computed DALYs by 
adding YLLs and YLDs for each age–sex–country group. 
We assumed that uncertainty in YLLs is independent of 
uncertainty in YLDs. We did this by summing the ﬁ rst 
draw of the 1000 draws for YLLs and YLDs and then 
repeating for each subsequent draw. We calculated 95% 
uncertainty intervals (UIs) using the 25th and 975th 
ordered draw of the DALY uncertainty distribution.
Healthy life expectancy
We calculated HALE in accordance with the methods 
outlined by Salomon and colleagues.8 In brief, we used 
Sullivan’s method22 to incorporate information about 
average levels of health experienced at diﬀ erent ages into 
Figure 2: Total DALYs, crude DALY rates, and age-standardised DALY rates from 1990 to 2013
Changes in global DALYs caused by communicable, maternal, neonatal, and nutritional disorders, non- communicable diseases, and injuries shown in terms of 
numbers of DALYs (A), DALY rates per 100 000 people (B), and age-standardised DALY rates per 100 000 people (C). The diﬀ erence in trends between A and B is 
caused by population growth and the diﬀ erence between B and C because of changes in the percentage distribution of the population by age. Shaded areas show 
95% uncertainty intervals. DALY=disability-adjusted life-years.
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Figure 3: Change in DALYs for GBD level 3 causes
Increasing and decreasing global DALYs for GBD level 3 causes from 1990 to 2005 (A) and 2005 to 2013 (B). Within each tree map, the size of the rectangle for each 
cause is proportional to the magnitude of the decrease or increase in DALYs for each cause. Dark shading show statistically signiﬁ cant changes and light shading 
shows changes that are not signiﬁ cant. Unmarked boxes represent causes for which the decrease or increase was less than 1 000 000 DALYs.  Table 1 and the appendix 
(p 4) contains numerical values for each cause. DALY=disability-adjusted life-years. GBD=Global Burden of Disease. Diarrhoea=diarrhoeal diseases. LRI=lower 
respiratory infections. NN enceph=neonatal encephalopathy due to birth asphyxia and trauma. NN haemol=haemolytic disease and other neonatal jaundice. Other 
NN=other neonatal disorders. NN preterm=preterm birth complications. Nematode=intestinal nematode infections. Iron=iron-deﬁ ciency anaemia. PEM=protein-
energy malnutrition. STD=sexually transmitted diseases excluding HIV. TB=tuberculosis. Whooping=whooping cough. NN sepsis=neonatal sepsis and other neonatal 
infections. Congenital=congenital anomalies. RHD=rheumatic heart disease. Oral=oral disorders. Sense=sense organ diseases. Cirr alc=cirrhosis due to alcohol use. 
Cirr hep C=cirrhosis due to hepatitis C. CKD=chronic kidney disease. CMP=cardiomyopathy and myocarditis. HTN HD=hypertensive heart disease. IHD=ischaemic heart 
disease. Stroke=cerebrovascular disease. Diabetes=diabetes mellitus. Alcohol=alcohol use disorders. Anxiety=anxiety disorders. Bipolar=bipolar disorder. Drugs=drug 
use disorders. Depression=depressive disorders. Other MSK=other musculoskeletal disorders. Back and neck=low back and neck pain. Breast C=breast cancer. 
Colorectal C=colon and rectum cancer. Liver C=liver cancer. Lung C=tracheal, bronchus, and lung cancer. Alzheimer’s=Alzheimer disease and other dementias. 
COPD=chronic obstructive pulmonary disease. Skin=skin and subcutaneous diseases. Fire=ﬁ re, heat, and hot substances. Mech=exposure to mechanical forces. 
War=collective violence and legal intervention. Violence=interpersonal violence. Road inj=road injuries. Haemog=haemoglobinopathies and haemolytic anaemias. 
ILD=interstitial lung disease and pulmonary sarcoidosis. Disaster=exposure to forces of nature.
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an abridged life table to produce estimates of life 
expectancy that are adjusted for reductions in functional 
health status relating to prevalent health conditions. 
Eﬀ ectively, the cumulative years lived in an age group in 
the abridged life table (the life expectancy column) for 
each country–age–sex group is multiplied by the YLDs 
per person for that country–age–sex group. Calculation 
of HALE relies on three inputs from GBD 2013: life 
tables by sex, country, and year; estimates of the 
prevalence of 2337 sequelae by age, sex, country and year; 
and disability weights for 235 unique health states that 
collectively cover the range of functional health losses 
and symptoms associated with the 2337 sequelae. Wang 
and colleagues2 have described data sources and methods 
to estimate mortality and life tables, and Vos and 




















































































 Communicable  Non-communicable  Injuries
1 Intestinal infectious diseases
2 Encephalitis
3 Other neglected tropical diseases
4 Other nutritional deﬁciencies
5 Pneumoconiosis
6 Other chronic respiratory diseases









16 Other cardiovascular and circulatory diseases
17 Interstitial lung disease and pulmonary 
 sarcoidosis
18 Cirrhosis due to hepatitis B
19 Cirrhosis due to other causes
20 Epilepsy
21 Medication overuse headache
22 Autistic spectrum disorders
23 Other mental and substance use disorders
24 Urinary diseases and male infertility
25 Gynaecological diseases
26 Haemoglobinopathies and 
       haemolytic anaemias
27 Rheumatoid arthritis
28 Exposure to forces of nature
1 Intestinal infectious diseases
2 Whooping cough
3 Maternal haemorrhage
4 Other infectious diseases
5 Stomach cancer
6 Alcohol use disorders
7 Fire, heat, and hot substances
8 Poisonings









18 Other cardiovascular and circulatory diseases
19 Cirrhosis due to hepatitis C
20 Medication overuse headache
21 Schizophrenia
22 Drug use disorders
23 Bipolar disorder
24 Other mental and substance use disorders
25 Urinary diseases and male infertility
26 Gynaecological diseases
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prevalence of sequelae and disability weights.1 We 
combined information about prevalence and disability 
weights into measures of the overall rate of YLDs per 
person in each age–sex–country group. We make the 
strong assumption that uncertainty in YLDs per person 
is independent of uncertainty in age-speciﬁ c death rates 
to calculate uncertainty distributions for HALE.
Decomposition of variance and epidemiological transition
The epidemiological transition is an extension of the 
notion of the demographic transition. In demographic 
transition, a characteristic evolution occurs in populations 
over time towards reduced fertility rates, reduced 
mortality rates, and an older age distribution of the 
population. The widely used concept of the 
epidemiological transition adds the idea that, in addition 
to these changes, a characteristic change occurs in the 
contributing causes of death. The epidemiological 
transition has been broadened to encompass the more 
general health transition, including both morbidity and 
mortality. A single variable to characterise countries over 
time in terms of their demographic and epidemiological 
status would be crucial to describe the epidemiological 
transition. Some studies examine associations with 
income per person, whereas others use variables such as 
mean age of the population.23,24 We aimed to construct a 
single composite variable to represent both demographic 
status and socioeconomic development to explore the 
patterns of the epidemiological transition. To construct 
this sociodemographic status variable, we assessed 
variables indicative of socioeconomic status and 
demographic change that were available for all 
188 countries from 1990 to 2013. We did not include 
measures of income inequality, such as the Gini 
coeﬃ  cient, because these were not available for all 
countries for each year. We used principal components 
analysis (PCA) of the log transformation of income per 
person (in constant international dollars), average years 
of schooling of the population after age 15 years, the log of 
the total fertility rate, and the log of the mean age of the 
population. The relationship between the PCA variables 
and DALY rates were highly non-linear, but became linear 
with respect to the log DALY rates after log transformation 
of three of the four sociodemographic status component 
variables. Before using PCA, we normalised each variable 
to have a mean of zero and a standard deviation of 1·0. 
Only the ﬁ rst component of the PCA had an eigenvalue 
greater than 1·0 and the weights were 0·471 for income 
per person, −0·517 for total fertility rate, 0·495 for 
education per person, and 0·516 for mean age.25 As 
expected, the sign on the total fertility rate was negative, 
whereas the sign on the other three components was 
positive. We also tested all possible combinations of the 
four variables using the same PCA approach to conﬁ rm 
that the principal component of all four was the most 
predictive of variation in DALY rates by cause. We used 
the predicted value of the ﬁ rst component for each 
country–year in the subsequent ANOVA and predictions 
Figure 4: 25 most common GBD level 3 causes of global DALYs for both sexes combined, 1990, 2005, and 2013, with age-standardised median percentage change
Ranks are based on the number of DALYs. 95% UIs for mean rank are from 1000 draws of DALYs. Communicable, maternal, neonatal, and nutritional disorders causes are shown in red, 
non-communicable causes in blue, and injuries in green. DALY=disability-adjusted life-years. GBD=Global Burden of Disease. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.
28 Chronic kidney disease 26 Alzheimer’s disease
27 Migraine
26 Protein–energy malnutrition
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2 Ischaemic heart disease
3 Diarrhoeal diseases
4 Cerebrovascular disease
5 Neonatal preterm birth
6 COPD




















21 Chronic kidney disease
12·1 (11–15) –35% (–42 to –30%)
12·5 (11–16) –10% (–22 to 2%)
13·8 (10–17) –5% (–6 to –4%)
14·1 (11–18) 3% (0 to 6%)
14·4 (13–16) 18% (15 to 22%)
14·6 (11–18) –14% (–22 to –5%)
17·1 (15–20) –21% (–25 to –18%)
18·9 (17–20) –11% (–14 to –8%)
18·9 (16–22) –8% (–18 to –1%)
19·9 (16–27) 0% (–2 to 1%)
21·7 (20–25) 13% (5 to 16%)
·
11·1 (9–15) 10 Neonatal encephalopathy
11·4 (10–14) 11 Malaria
12·5 (9–16) 12 Congenital anomalies
13·1 (9–19) 13 Sense organ diseases
13·9 (11–18) 14 Iron-deﬁciency anaemia
14·8 (10–22) 15 Depressive disorders
17·1 (15–20) 16 Diabetes
17·6 (12–24) 17 Other neonatal
18·3 (15–21) 18 Lung cancer
19·7 (16–24) 19 Self-harm
20·4 (11–35) 20 Measles
21·3 (16–29) 21 Drowning
22·4 (15–31) 22 Skin diseases
22·6 (17–28) 23 Protein–energy malnutrition






















10·6 (6–15) –36% (–45 to –22%)
11·4 (5–17) 1% (–2 to 4%)
11·8 (9–14) 1% (–2 to 4%)
12·1 (5–16) –3% (–5 to –2%)
13·5 (10–17) –18% (–27 to –7%)
13·6 (10–17) –5% (–16 to 2%)
15·7 (13–18) –27% (–32 to –21%)
17·5 (14–21) –12% (–14 to –10%)
18·5 (13–24) 0% (–2 to 2%)
18·5 (17–21) –7% (–12 to –3%)
20·4 (18–23) 0% (–4 to 4%)
21·0 (18–25) –17% (–25 to –8%)
24·0 (22–28) –13% (–18 to –9%)
24·2 (17–36) –6% (–21 to 13%)
25·2 (23–28) –2% (–6 to 1%)
23 Protein–energy malnutrition 24·4 (20–32) –21% (–30 to –12%)
24 Neonatal sepsis 24·9 (18–39) 11% (–9 to 39%)
25 Other neonatal 25·3 (20–32) –38% (–49 to –24%)
28 Drowning
1 Lower respiratory infections
6·4 (5–8)
9·2 (8–10) 9 Road injuries
24 3 (21–27) 25 Falls
1 Ischaemic heart disease 1·0 (1–1) –13% (–16 to –10%)
2 Cerebrovascular disease 2·3 (2–3) –14% (–17 to –11%)
3 Lower respiratory infections 2·7 (2–3)
4 Diarrhoeal diseases 4·8 (4–6) –46% (–49 to –42%)
–1% (–2 to 1%)
–39% (–42 to –35%)
6 6·3 (4–9) 35% (14 to 60%)
6 6·5 (4–9) 360% (280 to 438%)
5·4 (3–10)
8 8·1 (6–10) –20% (–25 to –15%)
8 8·3 (5–11) –33% (–39 to –24%)
9·8 (8–11) –2% (–10 to 2%)
22 Falls 22·7 (21–25) –7% (–18 to –4%)
1 Ischaemic heart disease 1·0 (1–1) –11% (–15 to –6%)
2 Cerebrovascular disease 2·2 (2–3) –14% (–17 to –10%)
3 Lower respiratory infections 3·4 (3–4) –22% (–28 to –15%)
4 Low back and neck pain 3·5 (2–5) 0% (–1 to 3%)
5·2 (5–7) –11% (–15 to –6%)
7·2 (5–11) –32% (–38 to –26%)
7·3 (5–10) –14% (–18 to –9%)
9·0 (5–14) –24% (–32 to –17%)
9·3 (6–12) –32% (–35 to –27%)
1990 leading causes
25 Migraine 26·0 (18–39) 1% (–2 to 3%)
Communicable, maternal, neonatal, and nutritionalKey Non–communicable Injuries 
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
All causes 2 513 239·2
(2 331 974·5 to 
2 717 184·5)
2 449 810·0





(38 101·1 to 
44 409·9)
35 523·9




Communicable, maternal, neonatal, 
and nutritional diseases
943 358·6
(903 197·4 to 985 632·0)
769 288·8




(13 434·2 to 
14 662·0)
10 606·9




HIV/AIDS and tuberculosis 150 304·0
(141 828·2 to 159 539·6)
119 179·6










(53 405·7 to 64 094·8)
49 816·2










(83 401·7 to 99 132·8)
69 363·4























HIV/AIDS resulting in other 
diseases
84 129·5
(77 516·6 to 92 482·2)
65 060·3









Diarrhoea, lower respiratory, and 
other common infectious diseases
316 908·8
(298 964·3 to 335 711·2)
249 855·1









Diarrhoeal diseases 99 453·9
(90 724·0 to 108 320·9)
72 796·6









Intestinal infectious diseases 17 538·4
(9936·1 to 28 497·3)
15 376·5









Typhoid fever 12 863·1
(7058·4 to 21 368·4)
11 127·8



































Lower respiratory infections 133 899·9
(124 847·7 to 142 498·1)
113 363·1


































(21 010·6 to 27 891·4)
21 014·9


















































































(2580·1 to 12 839·5)
5250·9






















(9981·3 to 28 573·5)
8015·1
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)
Neglected tropical diseases and 
malaria
121 587·6
(108 043·8 to 136 597·5)
90 676·8










(83 484·0 to 106 879·0)
65 493·1

























































































































































































































































Maternal disorders 21 717·2
(19 935·4 to 23 449·9)
18 027·8
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)


















































Neonatal disorders 221 687·5
(213 295·0 to 230 283·3)
189 601·0









Preterm birth complications 88 971·6
(75 761·9 to 108 464·4)
70 843·1










(birth asphyxia and trauma)
66 760·9
(53 355·4 to 77 432·1)
58 012·7









Sepsis and other neonatal 
infections
32 000·2
(19 472·8 to 44 418·3)
31 631·8























Other neonatal disorders 30 315·2
(24 647·8 to 38 101·8)
25 814·0









Nutritional deﬁ ciencies 79 695·9
(63 911·4 to 99 518·1)
74 834·4









Protein-energy malnutrition 29 772·1
(23 294·2 to 35 802·7)
27 709·9

































Iron-deﬁ ciency anaemia 46 359·5
(33 059·4 to 64 257·3)
43 747·6





















Other communicable, maternal, 
neonatal, and nutritional diseases
31 457·6
(24 584·5 to 39 680·1)
27 114·0









Sexually transmitted diseases 
excluding HIV
15 145·4
(9593·7 to 22 186·1)
12 857·2










(8228·6 to 20 649·7)
11 324·5
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change

























Other infectious diseases 9181·6
(5667·4 to 12 740·2)
7660·3









Non-communicable diseases 1 302 199·4
(1 155 437·8 to 
1 460 687·4)
1 432 938·8





(20 458·5 to 
25 487·7)
21 452·8





(175 482·3 to 185 592·2)
197 093·5










(7787·5 to 10 237·4)
9843·1









Stomach cancer 19 059·1
(18 331·4 to 19 926·9)
17 906·5









Liver cancer 19 175·3
(18 331·6 to 20 085·5)
20 888·7





































































Tracheal, bronchus, and 
lung cancer
30 791·6
(29 492·6 to 31 587·1)
34 732·9









Breast cancer 11 762·5
(10 713·2 to 13 178·0)
13 258·7













































Colon and rectum cancer 13 747·9
(13 378·9 to 14 138·6)
15 794·1
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change

























































































































Other neoplasms 11 023·4
(10 179·5 to 12 208·5)
12 027·7









Cardiovascular diseases 308 887·0
(294 356·7 to 324 066·8)
329 705·6









Rheumatic heart disease 10 103·6
(8576·3 to 12 982·8)
9517·7









Ischaemic heart disease 138 547·2
(127 675·5 to 149 798·3)
150 238·6









Cerebrovascular disease 107 737·1
(99 331·7 to 116 802·3)
112 878·9









Ischaemic stroke 44 730·9
(38 134·8 to 49 037·1)
47 424·7









Haemorrhagic stroke 63 006·2
(57 306·5 to 70 880·3)
65 454·2









Hypertensive heart disease 16 427·8
(13 746·5 to 19 904·3)
19 248·1









Cardiomyopathy and myocarditis 12 876·8
(10 178·6 to 14 361·3)
12 472·7

























































Other cardiovascular and 
circulatory diseases
17 032·8
(14 236·3 to 21 254·9)
18 298·8









Chronic respiratory diseases 104 250·7
(92 540·7 to 118 201·1)
112 710·7









Chronic obstructive pulmonary 
disease
66 478·5
(58 577·5 to 75 309·8)
71 900·7
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change






































(17 995·5 to 27 896·9)
22 182·7




































(34 221·3 to 36 967·4)
36 858·1









Cirrhosis due to hepatitis B 9321·9
(8709·4 to 9936·2)
9399·4









Cirrhosis due to hepatitis C 8937·8
(8404·8 to 9505·2)
9939·9









Cirrhosis due to alcohol use 11 182·1
(10 401·0 to 11 948·2)
10 886·3





















Digestive diseases 37 037·5
(33 945·1 to 40 627·4)
37 341·2









Peptic ulcer disease 9090·0



























































































































Neurological disorders 72 438·0
(56 404·6 to 91 027·3)
84 048·0









Alzheimer’s disease and other 
dementias
17 737·9
(16 089·2 to 19 551·9)
22 238·9






















(10 714·7 to 15 492·8)
13 372·1






















(15 613·2 to 37 987·5)
28 898·1
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change













Medication overuse headache 7577·4
(4426·0 to 11 589·5)
9845·7





















Mental and substance use 
disorders
157 899·7
(117 039·4 to 202 585·3)
173 177·4










(10 445·2 to 16 601·6)
15 687·2









Alcohol use disorders 13 856·3
(10 676·5 to 17 518·8)
12 772·1









Drug use disorders 16 573·6
(12 990·6 to 20 087·4)
17 953·0









Opioid use disorders 8577·2
(6762·8 to 10 512·9)
8136·2

























































Depressive disorders 54 086·1
(36 401·9 to 75 052·8)
61 632·8









Major depressive disorder 45 539·4
(29 829·4 to 64 133·2)
51 783·9










(5687·3 to 12 278·3)
9848·9










(5487·1 to 13 043·4)
9911·1









Anxiety disorders 21 949·1
(14 287·0 to 31 597·3)
24 355·8













































Autistic spectrum disorders 7721·8
(5369·6 to 10 463·8)
8449·0







































































Other mental and substance use 
disorders
8035·0
(5442·0 to 10 785·3)
9257·2
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)
Diabetes, urogenital, blood, and 
endocrine diseases
120 976·5
(101 712·4 to 143 463·1)
141 620·9









Diabetes mellitus 46 039·4
(38 599·7 to 54 434·2)
55 832·6





















Chronic kidney disease 28 349·4
(24 290·4 to 31 773·7)
33 187·2



















































Chronic kidney disease due to 
other causes
10 787·2
(8898·8 to 12 207·3)
13 135·4









Urinary diseases and male 
infertility
8848·5
(7381·2 to 10 580·7)
10 292·4










































































(5405·8 to 12 229·0)
9237·3


































































































(12 009·2 to 32 293·0)
23 368·9

































Sickle cell disorders 11 142·6
(3743·2 to 22 090·0)
13 650·5
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)
Glucose-6-phosphate 









































Musculoskeletal disorders 126 874·2
(91 296·7 to 167 000·8)
149 435·7






















(7337·3 to 14 133·8)
12 811·1









Low back and neck pain 91 729·2
(64 002·3 to 123 315·7)
106 665·5









Low back pain 61 611·0
(42 074·7 to 84 850·7)
72 317·6









Neck pain 30 118·2
(20 855·1 to 41 090·2)
34 347·9





















Other musculoskeletal disorders 20 290·1
(14 431·4 to 27 422·7)
25 032·4












(120 772·1 to 204 769·6)
170 947·9









Congenital anomalies 56 944·6
(49 141·0 to 69 460·2)
57 173·2









Neural tube defects 7161·8
(4444·2 to 12 759·5)
6236·6









Congenital heart anomalies 26 144·1
(22 321·2 to 32 868·8)
26 219·2







































































Other congenital anomalies 17 009·4
(13 826·2 to 25 442·3)
17 522·7









Skin and subcutaneous diseases 37 827·9
(25 158·8 to 56 628·8)
41 597·6










(5490·7 to 12 137·7)
9278·4
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All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)













(3360·8 to 12 916·9)
7180·8







































































Sense organ diseases 47 426·9
(31 917·8 to 66 335·1)
54 428·1













































Uncorrected refractive error 10 004·7
(6360·2 to 15 412·8)
11 257·2









Age-related and other hearing 
loss
28 010·5
(18 942·1 to 39 007·8)
32 579·7

































Oral disorders 14 385·1
(8778·2 to 22 332·8)
16 449·5




















































































(250 424·7 to 283 221·0)
247 582·4









Transport injuries 82 941·2
(75 570·2 to 87 805·0)
78 952·9









Road injuries 76 626·7
(70 107·3 to 81 166·5)
73 251·1









Pedestrian road injuries 26 400·1
(22 734·6 to 30 607·2)
25 580·0





















Motorcyclist road injuries 15 234·5
(12 694·2 to 17 550·9)
14 199·2
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of the epidemiological change with sociodemographic 
status.
We used hierarchical regression to decompose variance 
in log DALY rates into components related to the 
sociodemographic status, intercountry variation, year, 
and fraction explained by the interactions of the other 
variables. This approach estimates a simple model with 
uncorrelated random eﬀ ects for year, country, and 
sociodemographic status.26 We divided sociodemographic 
status into vigintiles (20 equal interval bins) to allow for 
non-linear correlations between log DALY rates and 
sociodemographic status for a cause. We did tests with 
up to 50 bins for the sociodemographic status variable 
with no change in qualitative results. We divided the 
variance of each random eﬀ ect by total variance to 
decompose variance into diﬀ erent factors. We did this 
variance decomposition analysis for GBD level 2 and 
level 3 causes. We use these regressions to predict the 
pattern of DALYs by cause (and through separate 
regressions for YLLs and YLDs) purely as a function of 
sociodemographic status, holding all other random 
eﬀ ects (year and country) at zero. Because there could be 
lagged eﬀ ects between sociodemographic status and 
DALY rate, we tested alternative models with 
All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)
Motor vehicle road injuries 28 677·5
(25 364·5 to 31 686·1)
27 692·3

































Unintentional injuries 112 792·0
(104 542·3 to 121 686·5)
105 941·3










(22 901·1 to 31 245·3)
27 491·4










(21 942·1 to 29 975·8)
21 608·0









Fire, heat, and hot substances 13 280·4
(11 575·9 to 15 303·6)
12 314·8





















Exposure to mechanical forces 14 798·4
(13 371·9 to 16 946·5)
14 037·9

































Other exposure to mechanical 
forces
9588·9
(8377·2 to 11 050·4)
8948·4







































































Pulmonary aspiration and 





































Other unintentional injuries 9948·8
(9059·1 to 10 862·9)
9291·4
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sociodemographic status lagged from 1 to 10 years. Use 
of sociodemographic status from the same year as the 
DALY rates explained, on average, the highest proportion 
of the variance in DALY rates.
Age standardisation
We selected the revised GBD 2013 world population 
standard for the age standardisation of rates. Details of 
the age standard, and its development, have been 
reported previously.2
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had access to the data in the study 
and ﬁ nal responsibility to submit the paper.
Results
Global
Global life expectancy at birth for both sexes combined 
increased from 65·3 years (95% UI 65·0–65·6) in 1990 to 
71·5 years (71·0–71·9) in 2013, whereas during the same 
interval, HALE at birth for both sexes combined increased 
from 56·9 years (54·5–59·1) to 62·3 years (59·7–64·8). 
The survivorship curves shift up and to the right with 
increasing quintiles of country sociodemographic status 
(ﬁ gure 1). In the three groups of countries, deﬁ ned as the 
lowest, middle three, and highest quintiles of country 
sociodemographic status in 2013, individuals are 
distributed across ranges of disability weights, with the 
majority of the population in most age groups living in 
health states with disability weights in the range 0·0–0·1. 
The fraction of individuals in the life table in full health 
(ie, living with a disability weight of zero) is 16·3% in the 
lowest sociodemographic status quintile of countries. 
Even in the most advantageous sociodemographic 
quintile of countries, the time lived in full health 
constitutes only a small fraction (17·5%) of the overall life 
course. At the other end of the spectrum, the expectation 
of years lived with disability weights greater than 0·5 is 
3·59 years in the lowest quintile and 6·60 years in the 
highest quintile of countries.
Figure 2 shows the need to understand global 
epidemiological change in terms of numbers, rates, and 
age-standardised rates. The number of DALYs caused by 
communicable, maternal, neonatal, and nutritional 
disorders has declined steadily from 1·19 billion 
(95% UI 1·15 billion to 1·24 billion) in 1990 to 
769·3 million (725·5 million to 814·9 million) in 2013, 
whereas DALYs for non-communicable diseases (NCDs) 
have increased steadily, rising from 1·08 billion 
(0·97 billion to 1·20 billion) to 1·43 billion (1·26 billion to 
1·61 billion) during the same period (ﬁ gure 2A). The year 
of crossover, during which global DALYs for NCDs 
exceeded those for global communicable, maternal, 
neonatal, and nutritional causes, was 1994. DALYs due to 
injuries have remained relatively constant, decreasing 
slightly from 269·6 million (251·6 million to 
286·7 million) to 247·6 million (231·3 million to 
265·1 million). Figure 2B shows crude DALY rates per 
100 000 people for these three broad cause groups, thereby 
removing the eﬀ ect of global population growth during 
the period. The DALY rate for NCDs has remained fairly 
constant, while substantial declines have occurred in 
All ages DALYs (thousands)* Age-standardised DALYs (per 100 000)*
2005 2013 Percentage change 2005 2013 Percentage change
(Continued from previous page)
Self-harm and interpersonal 
violence
60 826·5
(51 784·1 to 65 431·4)
56 574·6










(31 030·3 to 40 888·4)
35 170·4









Interpersonal violence 22 904·6
(17 216·9 to 27 308·2)
21 404·2









Assault by ﬁ rearm 9378·3
(6442·6 to 11 785·2)
9601·7

































Forces of nature, war, and legal 
intervention
11 121·5
(6687·7 to 18 862·5)
6113·6





















Collective violence and legal 
intervention
6997·9











Data are DALYs (95% UI) or % change (95% UI). UI=uncertainty interval. DALY=disability-adjusted life-years. *Percentage change is statistically signiﬁ cant (p<0·05).
Table 1: Global all-age DALYs and age-standardised DALYs for 306 causes in 2005 and 2013 with percentage change
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DALY rates for communicable, maternal, neonatal, and 
nutritional disorders (52·2%, 50·1–54·4) and injuries 
(32·0%, 27·0–35·9). The analysis of age-standardised 
DALY rates, shows that, after controlling for changes in 
population size and composition, NCD disease burden 
worldwide, has continued to decline, falling by 14·5% 
(11·6–17·3) between 1990 and 2013 (ﬁ gure 3C). During 
the same period, worldwide age-standardised DALY rates 
fell by 42·4% (40·0–45·0) for communicable, maternal, 
neonatal, and nutritional disorders and 30·9% 
(26·1–34·7) for injuries.
We decomposed the changes in the number of DALYs 
into trends for two periods: 1990–2005 and 2005–2013 
(ﬁ gure 3).10 Between 1990 and 2005, the number of global 
DALYs changed only slightly, from 2·54 billion 
(95% UI 2·40 billion to 2·70 billion) to 2·51 billion 
(2·33 billion to 2·72 billion). Looking at disease-level details 
within this relative stagnation reveals important trends for 
speciﬁ c diseases (ﬁ gure 3A); the earlier period was 
characterised by decreases in the number of DALYs from 
diarrhoea, lower respiratory infections, measles, neonatal 
causes, tuberculosis, and tetanus, with smaller 
contributions from declines in congenital causes and some 
injuries. Conversely, large increases in disease burden were 
recorded for HIV/AIDS and malaria, with smaller increases 
for road injuries and a diverse range of NCDs, including 
ischaemic heart disease, diabetes, low back and neck pain, 
stroke, and depression, in addition to several types of 
cancer. From 2005 to 2013, total DALYs worldwide 
decreased from 2·51 billion (2·33 billion to 2·72 billion) to 
2·45 billion (2·23 billion to 2·68 billion; ﬁ gure 3B). 
Decreases were recorded for diarrhoea, malaria, HIV/AIDS, 
lower respiratory infections, measles, tuberculosis, and 
neonatal causes, and nearly all injuries. Increases were 
noted for a wide range of NCDs, especially low back and 
neck pain, ischaemic heart disease, diabetes, chronic 
obstructive pulmonary disease (COPD), depression, stroke, 
and sense organ disorders. Although they were not large 
contributors to the number of DALYs, notable increases 
were seen for dengue, food-borne trematodes, and 
leishmaniasis. Separate analyses of changes in age-
standardised DALY rates for the period 2005–13 (data not 
shown) suggest that most of the increases shown in ﬁ gure 3 
are caused by ageing of the population and population 
growth.
We assessed changes in the age-standardised DALY 
rates of the leading GBD level 3 causes for 1990–2005 and 
2005–2013 (ﬁ gure 4; level 4 of the GBD cause hierarchy is 
reported in the appendix p 2). Between 1990 and 2005 
huge reductions occurred in measles, meningitis, iron-
deﬁ ciency anaemia, congenital anomalies, tuberculosis, 
drowning, protein-energy malnutrition, and some 
neonatal disorders, whereas disease burden from 
HIV/AIDS and malaria substantially increased (ﬁ gure 4). 
From 2005 to 2013, age-standardised DALY rates for 




A.1. HIV/AIDS and tuberculosis 20·65% 1·13% 73·09% 5·13%
A.2. Diarrhoea, lower respiratory, and other common infectious diseases 79·14% 0·76% 18·19% 1·91%
A.3. Neglected tropical diseases and malaria 14·04% 0·08% 84·98% 0·91%
A.4. Maternal disorders 80·34% 0·17% 17·75% 1·74%
A.5. Neonatal disorders 86·90% 0·25% 11·29% 1·56%
A.6. Nutritional deﬁ ciencies 80·48% 0·06% 17·12% 2·33%
A.7. Other communicable, maternal, neonatal, and nutritional diseases 56·61% 0·52% 40·94% 1·94%
B.1. Neoplasms 15·62% 0·28% 80·91% 3·19%
B.2. Cardiovascular diseases 3·01% 1·19% 88·69% 7·11%
B.3. Chronic respiratory diseases 6·41% 3·05% 82·74% 7·80%
B.4. Cirrhosis 1·18% 0·10% 90·78% 7·94%
B.5. Digestive diseases 17·49% 0·96% 76·95% 4·60%
B.6. Neurological disorders 45·38% 0·01% 53·01% 1·61%
B.7. Mental and substance use disorders 28·62% 0·37% 68·41% 2·60%
B.8. Diabetes, urogenital, blood, and endocrine diseases 8·77% 1·85% 83·05% 6·33%
B.9. Musculoskeletal disorders 65·71% 0·02% 33·30% 0·96%
B.10. Other non-communicable diseases 57·14% 1·05% 33·72% 8·08%
C.1. Transport injuries 21·39% 1·76% 63·26% 13·58%
C.2. Unintentional injuries 4·58% 6·27% 80·81% 8·33%
C.3. Self-harm and interpersonal violence 2·61% 0·36% 91·23% 5·80%
C.4. Forces of nature, war, and legal intervention 24·54% 1·18% 55·63% 18·65%
DALY=disability-adjusted life-years. GBD=Global Burden of Disease.
Table 2: Decomposition of variance in 2013 global DALY rates per 100 000 people for GBD level 2 causes using hierarchical regression
See Online for appendix
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cerebrovascular disease have declined, although not 
suﬃ  ciently for these conditions to be replaced as the 
leading causes of disease burden worldwide. The ranks of 
low back and neck pain, road injuries and COPD have all 
increased since 2005. Age-standardised rates decreased 
signiﬁ cantly for 16 of the 25 leading causes of DALYs in 
2013; for the remaining nine causes (Alzheimer’s disease, 
chronic kidney disease, congenital anomalies, depressive 
disorders, diabetes, low back and neck pain, migraine, 
neonatal sepsis, and skin diseases), age-standardised 
rates did not signiﬁ cantly change.
Table 1 shows DALYs for each cause in 2005 and 2013 
and changes in numbers and age-standardised rates of 
the DALYs (for the same information for 1990 to 2013 see 
appendix p 4).
Decomposition of epidemiological patterns
We decomposed the variance of DALY rates for GBD 
level 2 causes into contributions from sociodemographic 
status, year, country, and unexplained sources (residual; 
table 2). Sociodemographic status explained more than 
50% of the variance for diarrhoea, lower respiratory 
infections and other common infectious diseases; 
maternal disorders; neonatal disorders; nutritional 
deﬁ ciencies; other communicable diseases; 
musculoskeletal disorders; and other NCDs. 
Furthermore, sociodemographic status explains between 
a ﬁ fth and a half of the variance for HIV/AIDS and 
tuberculosis; neurological disorders; mental and 
substance use disorders; transport injuries; and forces of 
nature, war, and legal intervention. Sociodemographic 
status explained little of the variance in the DALY rates 
for neglected tropical diseases and malaria, for which 
time-invariant country diﬀ erences account for 84·98% of 
the variance. Notably, less than 10% of the variance in the 
burden of several level 2 causes could be related to 
sociodemographic status, including cardiovascular 
diseases; chronic respiratory diseases; cirrhosis; diabetes, 
urogenital, blood, and endocrine diseases; unintentional 
injuries; and self-harm and interpersonal violence. Year 
explained less than 7% of variance for all causes. By 
contrast, time invariant intercountry variation was an 
important component of the variance in DALY rates for 
all causes, ranging from a low of 11·29% for neonatal 
disorders to 91·23% for self-harm and interpersonal 
violence. Intercountry variation explains more than two-
thirds of the total variance in DALY rates for HIV/AIDS 
and tuberculosis; neglected tropical diseases and malaria; 
neoplasms; cardiovascular diseases; chronic respiratory 
diseases; cirrhosis; digestive diseases; mental and 
substance use disorders; diabetes, urogenital, blood, and 
endocrine disorders; unintentional injuries; and self-
harm and interpersonal violence. Notably, together, 
sociodemographic status and country account for more 
than 90% of the variance for 17 of 21 GBD level 2 causes; 
indeed, the lowest fraction of variance accounted for by 
these three factors is 80·2% for forces of nature, war, and 
legal intervention.
Figure 5: YLL and YLD cause composition of DALY rates by sociodemographic status vigintile
The epidemiological transition based on predicted YLL and YLD rates per 100 000 people as a function of the level of sociodemographic status by vigintile and broken 
down into GBD level 2 causes. These predicted levels control for variation explained by year and country. YLL= years of life lost. YLD=years lived with disability. 
GBD=Global Burden of Disease.
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Figure 5 shows the predicted global composition of 
YLLs and YLDs for level 2 causes at diﬀ erent levels of 
sociodemographic status, controlling for year and 
country. YLLs from diarrhoea, lower respiratory 
infections, and other common infections, and neonatal 
disorders fall substantially as sociodemographic status 
increases. Other YLLs that fall noticeably with rising 
sociodemographic status include YLLs from maternal 
causes, nutritional deﬁ ciencies, other non-communicable 
causes (including congenital causes), and unintentional 
injuries. YLLs from cardiovascular diseases at ﬁ rst 
increase slightly with increasing sociodemographic 
status, but then decrease at the highest levels of country 
sociodemographic status. Some important causes of 
global YLLs are not strongly related to sociodemographic 
status because they are largely country-speciﬁ c, such as 
neglected tropical diseases and malaria, neoplasms, and 
intentional injuries. By contrast, overall YLDs decline 
slightly at ﬁ rst, but then increase substantially, showing 
the opposite trend to YLLs. The large increases in YLDs 
are related to musculoskeletal disorders; mental and 
substance use disorders; diabetes, urogenital, blood, and 
endocrine diseases; and neurological disorders. As 
sociodemographic status rises, the steady decreases in 
YLLs and increases in YLDs cause the proportion of total 
DALYs attributable to YLDs to steadily rise from 9·9% at 
the lowest level of sociodemographic status to 49·1% in 
the highest vigintile. Above the tenth vigintile of 
sociodemographic status, the rise in YLDs and fall in 
YLLs nearly compensate for each other so that DALY 
rates have remained largely constant.
Country-speciﬁ c results
In 1990, life expectancy ranged from 46·9 years 
(95% UI 45·1–48·2) in the Central African Republic to 
80·7 years (78·7–82·5) in Andorra, while HALE ranged 
from 40·4 years (38·2–42·5) in the Central African 
Republic to 70·2 years (67·7–72·5) in Japan. By 2013, life 
expectancy ranged from 48·3 years (46·5–50·1) in 
Lesotho to 83·9 years (82·3–85·5) in Andorra, and HALE 
 1990 2005 2013










































































































































































































































































































































































































Data are years (95% uncertainty interval). HALE=healthy life expectancy.
Table 3: Life expectancy at birth and HALE at birth for 1990, 2005, and 2013 for both sexes and 188 countries
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(Figure 6 continues on next page)
1 2 3 4 5 6 7 8 9 10
Global IHD LRI Stroke Back & neck Road inj Diarrhoea COPD NN preterm HIV/AIDS Malaria
Developed IHD Back & neck Stroke Lung C Depression COPD Sense Diabetes Alzheimer’s Falls
Developing IHD LRI Stroke Back & neck Diarrhoea NN preterm HIV/AIDS Road inj Malaria COPD
High-income Back & neck IHD Stroke Lung C COPD Depression Diabetes Alzheimer’s Sense Other MSK
Australasia Back & neck IHD Depression Other MSK COPD Alzheimer’s Lung C Stroke Diabetes Sense
Australia Back & neck IHD Depression Other MSK COPD Alzheimer’s Lung C Stroke Diabetes Sense
New Zealand Back & neck IHD COPD Depression Alzheimer's Lung C Stroke Diabetes Sense Other MSK
High-income Asia Pacific Back & neck Stroke IHD Diabetes Lung C Self-harm Other MSK LRI Sense Depression
Brunei Back & neck IHD Diabetes Stroke Depression Road inj Congenital Skin Iron Other MSK
Japan Back & neck Stroke IHD LRI Lung C Other MSK Diabetes Sense Self-harm Depression
Singapore IHD Depression Diabetes Back & neck LRI Stroke Sense Other MSK Lung C Skin
South Korea Back & neck Stroke Diabetes Self-harm IHD Liver C Lung C Other MSK Stomach C Migraine
High-income North America IHD Back & neck COPD Lung C Depression Diabetes Alzheimer's Other MSK Stroke Sense
Canada Back & neck IHD Lung C Other MSK Alzheimer's Diabetes Sense Depression COPD Stroke
USA IHD Back & neck COPD Lung C Depression Diabetes Alzheimer's Other MSK Stroke Sense
Southern Latin America IHD Back & neck COPD Stroke Depression LRI Road inj Congenital Diabetes Skin
Argentina IHD COPD Back & neck Stroke LRI Depression Road inj Congenital Diabetes Skin
Chile Back & neck IHD Stroke Depression COPD Road inj Skin Congenital Anxiety CKD
Uruguay IHD Stroke Back & neck COPD Alzheimer’s Lung C Depression Road inj Sense LRI
Western Europe Back & neck IHD Stroke Lung C Alzheimer’s Sense Falls Depression COPD Diabetes
Andorra Back & neck IHD Stroke Sense Lung C Depression Alzheimer’s Falls COPD Skin
Austria IHD Back & neck Stroke Alzheimer's Lung C Sense Falls Depression Diabetes COPD
Belgium Back & neck IHD Lung C COPD Alzheimer's Stroke Falls Road inj Sense Self-harm
Cyprus Back & neck IHD Diabetes Depression Stroke Sense Alzheimer’s Skin Lung C CKD
Denmark Back & neck IHD COPD Stroke Lung C Alzheimer’s Falls Depression Skin Colorect C
Finland IHD Back & neck Falls Alzheimer’s Stroke Depression Diabetes Sense Lung C Self-harm
France Back & neck IHD Lung C Falls Depression Sense Stroke Skin Alzheimer's Self-harm
Germany Back & neck IHD Stroke Sense Alzheimer’s Lung C Diabetes COPD Falls CKD
Greece IHD Back & neck Stroke Lung C COPD Alzheimer’s Sense Depression CKD Falls
Iceland Back & neck IHD Skin COPD Sense Alzheimer’s Lung C Depression Diabetes Stroke
Ireland IHD Back & neck Depression COPD Lung C Stroke Skin Sense Falls Diabetes
Israel Back & neck IHD Depression Diabetes Alzheimer's CKD Skin Sense COPD Lung C
Italy Back & neck IHD Alzheimer’s Sense Stroke Lung C Falls Depression Migraine COPD
Luxembourg Back & neck IHD Stroke Lung C COPD Depression Migraine Sense Falls Diabetes
Malta Back & neck IHD Diabetes Stroke Depression Sense Lung C Falls CKD COPD
Netherlands Back & neck IHD Lung C COPD Skin Stroke Diabetes Sense Depression Alzheimer’s
Norway Back & neck IHD Alzheimer’s Stroke Lung C Falls COPD Anxiety Depression Skin
Portugal Back & neck Stroke IHD Diabetes Depression Alzheimer’s Sense Lung C CKD COPD
Spain Back & neck IHD Diabetes Stroke COPD Alzheimer’s Depression Lung C Sense Falls
Sweden Back & neck IHD Stroke Falls COPD Depression Sense Alzheimer’s Lung C Skin
Switzerland Back & neck IHD Falls COPD Alzheimer’s Stroke Sense Lung C Depression Skin
UK Back & neck IHD Stroke COPD Lung C Alzheimer’s Sense Depression Falls Skin
England Back & neck IHD Stroke COPD Lung C Alzheimer’s Sense Depression Falls Skin
Northern Ireland IHD Back & neck Depression Lung C Stroke COPD Alzheimer’s Falls Skin Sense
Scotland Back & neck IHD Lung C Stroke COPD Alzheimer’s Sense Diabetes Falls Skin
Wales Back & neck IHD Stroke COPD Lung C Alzheimer’s Depression Sense Falls Diabetes
Central Europe, eastern Europe, and central Asia IHD Stroke Back & neck LRI Self-harm Depression Sense Lung C Road inj COPD
Central Asia IHD LRI Stroke NN enceph Back & neck Congenital Road inj Depression Diabetes NN preterm
Armenia IHD Stroke Diabetes Back & neck Lung C Depression Sense Road inj Congenital COPD
Azerbaijan IHD LRI Stroke Back & neck Diabetes NN enceph Depression Congenital Road inj Sense
Georgia IHD Stroke COPD Diabetes Back & neck Sense Depression Falls Alzheimer’s Road inj
Kazakhstan IHD Stroke Self-harm Back & neck Road inj Congenital LRI COPD NN enceph Depression
Kyrgyzstan IHD Stroke LRI NN enceph NN preterm Congenital Back & neck Road inj COPD Depression
Mongolia IHD Stroke LRI Liver C NN enceph Congenital Self-harm Road inj NN preterm Back & neck
Tajikistan LRI IHD NN preterm Diarrhoea NN enceph Congenital Stroke Back & neck Depression Drown
Turkmenistan IHD LRI Stroke NN enceph Diarrhoea Back & neck Congenital NN preterm Depression Diabetes
Uzbekistan IHD LRI Stroke NN enceph Back & neck Road inj Depression Diabetes Congenital HTN HD
Central Europe IHD Stroke Back & neck Lung C Falls COPD Sense Diabetes Depression Alzheimer’s
Albania IHD Stroke Back & neck Depression LRI Falls Lung C Sense COPD Diabetes
Bosnia and Herzegovina IHD Stroke Back & neck Diabetes Lung C CMP COPD Sense Depression Falls
Bulgaria IHD Stroke Back & neck COPD Diabetes HTN HD Falls Lung C Sense Alzheimer’s
Croatia IHD Stroke Back & neck Lung C Sense COPD Diabetes Alzheimer’s Depression Falls
Czech Republic IHD Back & neck Stroke Falls Lung C Sense Diabetes COPD Depression Alzheimer’s
Hungary IHD Stroke Back & neck Lung C Falls COPD Sense Diabetes Colorect C Depression
Macedonia Stroke IHD Back & neck Diabetes Lung C Depression Sense Falls COPD CKD
Montenegro IHD Stroke Back & neck Lung C Diabetes Sense Falls Depression Self-harm CKD
Poland IHD Stroke Back & neck Lung C Falls COPD Sense Depression Diabetes Self-harm
Romania IHD Stroke Back & neck Falls Lung C Sense Depression COPD Diabetes Alzheimer’s
Serbia IHD Stroke Back & neck CMP Lung C Diabetes Sense COPD Depression Alzheimer’s
Slovakia IHD Back & neck Stroke Falls Lung C Sense Depression Diabetes Colorect C COPD
Slovenia Back & neck IHD Falls Stroke Lung C Sense Depression COPD Alzheimer’s Diabetes
Eastern Europe IHD Stroke Back & neck Self-harm CMP Depression Sense Alcohol Lung C Road inj
Belarus IHD Stroke Back & neck Self-harm Road inj Lung C Depression Sense COPD Alcohol
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LRI NN preterm IHD Stroke Diarrhoea Road inj Congenital NN enceph Iron TB
IHD Road inj Stroke LRI Diabetes Back & neck COPD Skin Depression Nematode
IHD Back & neck Congenital Stroke COPD Sense NN enceph Diabetes Skin NN preterm
Cambodia IHD LRI NN preterm War Stroke Congenital Road inj Iron TB OPD




IHD LRI Stroke Back & neck TB NN preterm Congenital Diabetes COPD Iron
IHD Self-harm Diabetes COPD Back & neck Stroke Sense Road inj Asthma Depression
IHD Road inj Stroke Diabetes LRI Sense COPD CKD Liver C HIV/AIDS
LRI NN preterm Diarrhoea Congenital IHD Iron Stroke Other NN NN enceph Road inj
Stroke Road inj Back & neck Sense LRI NN preterm Liver C Depression War COPD
IHD LRI NN enceph NN preterm Diarrhoea COPD TB Stroke Back & neck Road inj
LRI Diarrhoea NN preterm IHD Congenital Road inj Stroke Iron Meningitis Other NN
Stroke Back & neck NN enceph IHD NN preterm LRI COPD Drown Iron Depression
IHD LRI NN enceph Stroke Back & neck NN preterm COPD Road inj Depression Diabetes
IHD COPD TB LRI NN preterm NN enceph Diarrhoea Stroke Road inj Back & neck
Belarus IHD Stroke Back & neck Self-harm Road inj Lung C Depression Sense COPD Alcohol
Estonia IHD Stroke Back & neck Depression Lung C Sense Alzheimer's Alcohol Diabetes HTN HD
Latvia IHD Stroke Back & neck Sense CMP Lung C Alzheimer's Self-harm Depression Diabetes
Lithuania IHD Stroke Back & neck Self-harm Sense Depression Lung C Alzheimer’s COPD Road inj
Moldova IHD Stroke Back & neck Depression Cirr HepC Sense LRI COPD Self-harm Lung C
Russia IHD Stroke Back & neck CMP Self-harm Depression Alcohol Sense Road inj Lung C
Ukraine IHD Stroke Back & neck Depression Self-harm Sense HIV/AIDS Lung C Road inj COPD
Latin America and Caribbean
Andean Latin America
IHD
LRI Road inj IHD Back & neck Congenital Depression NN preterm Sense Stroke F Body
Violence Back & neck Road inj Diabetes Depression Stroke LRI Congenital Sense
Bolivia LRI F Body Road inj NN preterm IHD Congenital NN enceph Back & neck Depression Diarrhoea
Ecuador LRI Road inj IHD Congenital Violence Back & neck Depression CKD Stroke Sense
Peru LRI Back & neck IHD Depression Road inj Sense Congenital COPD NN preterm Stroke
Caribbean IHD Stroke Diabetes LRI HIV/AIDS Road inj Depression Diarrhoea Back & neck Congenital
Antigua and Barbuda Diabetes IHD Stroke Depression Back & neck Sense Road inj Iron CKD LRI
Barbados Diabetes IHD Stroke Back & neck Depression Sense CKD LRI COPD Skin
Belize Diabetes IHD Stroke Violence Road inj NN preterm Depression Congenital Iron HIV/AIDS
Cuba IHD Stroke Diabetes Sense Depression Lung C Back & neck COPD LRI Road inj
Dominica Diabetes IHD Stroke Depression Back & neck Road inj Sense LRI CKD NN preterm
Dominican Republic IHD Road inj Stroke NN preterm Congenital Diabetes Depression Back & neck LRI Violence
Grenada IHD Diabetes Stroke Road inj Depression Back & neck LRI Sense HIV/AIDS Violence
Guyana IHD HIV/AIDS Stroke Diabetes Road inj Congenital LRI Self-harm Violence NN preterm
Haiti HIV/AIDS LRI Diarrhoea Stroke PEM NN sepsis Iron IHD NN preterm Congenital
Jamaica Diabetes Stroke IHD Violence Depression Back & neck NN preterm Sense CKD Congenital
Saint Lucia Diabetes IHD Stroke Depression Back & neck Sense Violence Road inj LRI COPD
Saint Vincent and the Grenadines IHD Diabetes Stroke Depression Back & neck NN preterm Road inj HIV/AIDS Violence Sense
Suriname IHD Stroke Diabetes NN preterm Congenital Road inj LRI Depression HIV/AIDS Back & neck
The Bahamas IHD Diabetes Stroke HIV/AIDS Depression Back & neck Violence Road inj CKD Sense
Trinidad and Tobago Diabetes IHD Stroke Road inj Violence Depression Back & neck CKD Sense HIV/AIDS
Central Latin America Violence IHD Diabetes Back & neck Road inj Depression CKD Congenital LRI Sense
Colombia Violence IHD Depression Back & neck Road inj Congenital COPD Stroke Diabetes Sense
Costa Rica Back & neck IHD Depression Road inj Sense Congenital CKD COPD Asthma Diabetes
El Salvador Violence IHD Road inj Back & neck CKD Congenital Diabetes LRI Depression Iron
Guatemala LRI Violence Diarrhoea NN preterm Back & neck IHD Iron Congenital Diabetes PEM
Honduras IHD Congenital Violence Depression NN preterm COPD Back & neck Stroke Diarrhoea LRI
Mexico Diabetes IHD CKD Back & neck Depression Road inj Congenital Violence Sense COPD
Nicaragua Congenital CKD Back & neck War Depression LRI IHD NN preterm Diabetes Road inj
Panama Back & neck IHD Congenital Depression Violence Road inj Diabetes Stroke Sense CKD
Venezuela Violence IHD Road inj Back & neck Diabetes Depression Stroke Congenital Sense CKD
Tropical Latin America IHD Back & neck Violence Stroke Road inj Diabetes Depression Anxiety COPD Sense
Brazil IHD Back & neck Violence Stroke Road inj Diabetes Depression Anxiety COPD Sense
Paraguay IHD Road inj Back & neck Stroke Congenital Diabetes NN preterm Depression LRI Violence
Southeast Asia, east Asia, and Oceania Stroke IHD Back & neck Road inj COPD Diabetes Sense Lung C Depression LRI
East Asia Stroke Back & neck IHD COPD Road inj Lung C Sense Depression Diabetes Liver C
Stroke Back & neck IHD COPD Road inj Lung C Depression Sense Diabetes Liver C
Stroke IHD Back & neck COPD Lung C Road inj Liver C Stomach C Sense Congenital
China
North Korea
Taiwan (province of China) Back & neck Diabetes IHD Stroke Liver C Sense Road Inj Lung C Skin Self-harm
Oceania LRI IHD Diabetes Diarrhoea Malaria Congenital NN preterm Stroke Road inj Other NN
Federated States of Micronesia IHD Diabetes Stroke LRI Congenital Road inj Back & neck Skin COPD Asthma
Fiji IHD Diabetes Stroke LRI Congenital NN preterm Back & neck CKD COPD Sense
Kiribati Diabetes Stroke IHD LRI Other NN Congenital Road inj Diarrhoea Asthma Back & neck
Marshall Islands IHD Diabetes LRI Stroke Congenital NN preterm Road inj Other NN Back & neck CKD
Papua New Guinea LRI IHD Diarrhoea Diabetes Malaria NN preterm Congenital Other NN Road inj HIV/AIDS
Samoa Diabetes IHD Stroke Back & neck LRI Congenital Skin Sense CKD Road inj
Solomon Islands IHD Diabetes Stroke LRI Diarrhoea Congenital NN preterm Back & neck Asthma TB
Tonga IHD Diabetes LRI Stroke NN preterm Back & neck Congenital Road inj Skin Other NN
Vanuatu IHD Diabetes LRI Stroke NN preterm Congenital Other NN Road inj Diarrhoea Back & neck
Southeast Asia Stroke IHD LRI Road inj TB Diabetes Back & neck NN preterm Sense COPD
C
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(Figure 6 continues on next page)
IHD COPD TB LRI NN preterm NN enceph Diarrhoea Stroke Road inj Back & neck
LRI IHD Back & neck NN enceph Diarrhoea Stroke COPD TB Self-harm NN preterm
LRI NN enceph Diarrhoea IHD NN preterm NN sepsis Stroke Meningitis Road inj Congenital
IHD Back & neck Congenital NN preterm Stroke Diabetes Road inj Depression LRI COPD
NN preterm IHD Back & neck Congenital Road inj Stroke Diabetes Depression Sense Iron
Diabetes Back & neck Drugs Depression IHD Road inj Skin Sense Iron Congenital
IHD Stroke Back & neck Congenital COPD LRI Diabetes Cirr hep C Sense Other cardio
IHD Back & neck Congenital NN preterm Depression Road inj Diabetes Sense Stroke Drugs
NN preterm IHD Congenital Stroke Diabetes Back & neck LRI Iron CKD Road inj
Congenital Back & neck NN preterm Diabetes IHD Depression Drugs Iron Skin LRI
IHD Diabetes Depression Drugs Congenital Road inj Back & neck Skin Sense NN preterm
IHD Diabetes Depression Back & neck Congenital Skin War COPD Stroke Drugs
IHD Back & neck Diabetes Congenital Stroke Depression Road inj NN preterm COPD Iron
Back & neck NN preterm IHD Diabetes Drugs Depression Stroke Road inj Congenital NN enceph
Road inj Back & neck IHD Diabetes Depression Sense Congenital Drugs Skin Stroke
Congenital IHD Depression Back & neck Diabetes Stroke NN preterm LRI Iron Road inj
Drugs Back & neck Road inj Depression Diabetes Skin Congenital IHD NN preterm Sense
Road inj Diabetes Back & neck IHD Depression Congenital Drugs NN preterm Skin Stroke
NN preterm IHD Congenital Diarrhoea LRI Stroke Back & neck Road inj Iron Malaria
War IHD Stroke Back & neck Depression Congenital Diabetes Iron Migraine COPD
IHD Back & neck Road inj Stroke Depression Congenital Diabetes COPD Sense NN preterm
IHD Back & neck COPD Diabetes Congenital Stroke Lung C Depression Road inj NN preterm
Road inj Back & neck Drugs Depression IHD Diabetes Skin Congenital Sense COPD
NN preterm IHD Diarrhoea Congenital LRI Stroke Iron Malaria Road inj Back & neck
HIV/AIDS Malaria LRI Diarrhoea NN preterm PEM NN enceph Congenital TB Road inj
LRI Diarrhoea Malaria PEM HIV/AIDS NN preterm Congenital TB NN enceph Meningitis
LRI Diarrhoea HIV/AIDS Malaria Congenital PEM NN preterm TB NN enceph Road inj
HIV/AIDS LRI Diarrhoea Malaria TB NN preterm PEM STD Meningitis NN enceph
HIV/AIDS LRI Malaria Congenital Stroke Diarrhoea NN preterm NN enceph Measles TB
Diarrhoea LRI Malaria PEM NN preterm HIV/AIDS Congenital TB NN enceph Iron
HIV/AIDS LRI Malaria Congenital Road inj Diarrhoea Stroke NN preterm PEM NN enceph
HIV/AIDS LRI Malaria Stroke Road inj Congenital TB Diarrhoea IHD NN enceph
HIV/AIDS LRI Malaria Diarrhoea TB NN preterm NN enceph PEM NN sepsis Congenital
Malaria LRI Diarrhoea TB HIV/AIDS NN preterm PEM NN enceph NN sepsis Congenital
LRI Diarrhoea TB NN preterm Malaria NN enceph Stroke NN sepsis Road inj Congenital
HIV/AIDS LRI Malaria Diarrhoea TB Stroke NN enceph Depression PEM Congenital
Diarrhoea LRI TB HIV/AIDS Malaria Iron NN preterm PEM Depression Meningitis
LRI Diarrhoea HIV/AIDS TB NN preterm NN enceph Malaria NN sepsis Congenital Meningitis
HIV/AIDS LRI Diarrhoea TB NN preterm Malaria NN enceph Congenital PEM NN sepsis
LRI Diarrhoea Stroke NN preterm PEM Malaria STD Iron Depression Congenital
HIV/AIDS LRI Diarrhoea PEM Malaria TB NN preterm Congenital NN enceph Meningitis
Diabetes IHD Stroke CKD Back & neck Sense COPD Road inj Depression LRI
HIV/AIDS Malaria LRI Diarrhoea TB NN sepsis NN enceph NN preterm STD Road inj
HIV/AIDS LRI Malaria Diarrhoea NN preterm War NN enceph Road inj TB NN sepsis
IHD Stroke LRI Diabetes Back & neck HTN HD Sense COPD Road inj Depression
Diarrhoea LRI Malaria TB PEM Meningitis NN preterm NN enceph Tetanus Other NN
LRI Diarrhoea HIV/AIDS TB PEM Meningitis Malaria STD NN preterm NN enceph
HIV/AIDS LRI Malaria Diarrhoea TB Congenital PEM NN enceph STD NN preterm
HIV/AIDS Malaria LRI Diarrhoea NN preterm NN enceph TB NN sepsis PEM Road inj
HIV/AIDS Malaria LRI Diarrhoea PEM TB NN enceph Congenital NN sepsis Meningitis
HIV/AIDS LRI Diarrhoea TB Back & neck Violence NN preterm Stroke Diabetes Road inj
HIV/AIDS TB LRI Diarrhoea Back & neck NN preterm Road inj Depression Other NN Self-harm
HIV/AIDS TB Diarrhoea LRI NN preterm Violence Other NN NN enceph Road inj Self-harm
HIV/AIDS TB LRI Diarrhoea Stroke Self-harm Road inj NN preterm Other NN Back & neck
HIV/AIDS LRI TB Diarrhoea Back & neck Diabetes Violence Stroke COPD Road inj
HIV/AIDS LRI TB Diarrhoea Road inj NN preterm Other NN Violence Self-harm Stroke
HIV/AIDS LRI Diarrhoea TB NN preterm NN enceph Stroke PEM Malaria Road inj
Malaria LRI HIV/AIDS Diarrhoea NN preterm NN enceph Haemog Road inj PEM NN sepsis
Malaria LRI HIV/AIDS Diarrhoea NN preterm NN enceph Congenital Iron Road inj NN sepsis
Malaria LRI Diarrhoea NN preterm Congenital Meningitis NN enceph Road inj HIV/AIDS NN sepsis
HIV/AIDS Malaria LRI Diarrhoea Road inj NN preterm NN enceph Congenital PEM NN sepsis
Stroke Back & neck Depression Congenital IHD LRI Iron COPD Sense Skin
Diarrhoea LRI Malaria HIV/AIDS PEM NN preterm Meningitis NN enceph Iron Congenital
LRI HIV/AIDS Malaria Diarrhoea NN preterm NN enceph Road inj NN sepsis Congenital PEM
Malaria LRI HIV/AIDS NN sepsis NN preterm PEM NN enceph Stroke Road inj Iron
Malaria LRI Diarrhoea HIV/AIDS NN preterm NN enceph PEM NN sepsis Meningitis Road inj
Malaria HIV/AIDS LRI Diarrhoea NN preterm PEM NN enceph Meningitis Road inj Congenital
Malaria LRI Diarrhoea HIV/AIDS NN preterm NN enceph PEM TB NN sepsis Congenital
Malaria Diarrhoea LRI PEM NN preterm NN enceph Iron Meningitis NN sepsis Congenital
LRI Malaria Diarrhoea NN enceph NN preterm Road inj Congenital Iron NN sepsis Stroke
Malaria Diarrhoea LRI PEM NN preterm Meningitis Iron Congenital NN enceph NN sepsis
Malaria LRI HIV/AIDS Haemog Road inj NN preterm NN enceph Diarrhoea PEM NN sepsis
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ranged from 42·0 years (39·8–44·2) in Lesotho to 
73·4 years (70·5–76·0) in Japan. Disaggregating by sex, 
in 1990, there were no countries in which men had 
attained a HALE of 70 years or more, and only in Japan 
and Andorra did women attain this. By 2013, HALE for 
men exceeded 70 years in only two countries (Japan and 
Singapore), whereas HALE for women exceeded 70 years 
in 40 countries (table 3). Of the 21 GBD regions, nine 
contained at least one country in which female HALE 
was at least 70 years in 2013. For most countries, changes 
in HALE were positive for both men and women between 
1990 and 2013, and the diﬀ erences were signiﬁ cant. 
However, HALE in 2013 was not signiﬁ cantly higher 
than it was in 1990 in 43 countries for men and in 
32 countries for women. As life expectancy increases, the 
gap between life expectancy and HALE widens, 
increasing to more than 10 years at a life expectancy of 
77 years for women and 78 years for men. The life 
expectancy minus HALE divided by life expectancy (the 
percentage of life expectancy lost because of poor health) 
ranged between 11·5% and 15·0%.
Figure 6 shows the ten most common causes of DALYs 
for each country in 2013. The leading causes of DALYs 
vary substantially across regions, representing both 
diﬀ erent levels of sociodemographic status and distinct 
regional patterns. In high-income regions, low back and 
neck pain, ischaemic heart disease, cerebrovascular 
disease, and tracheal, bronchus, and lung cancer are often 
among the four most common causes, although major 
depression, COPD, and diabetes come into the top four 
slots in some countries. In central and eastern Europe, 
cardiovascular diseases rank consistently in the most 
common causes of DALYs. Self-harm and depression 
frequently rank higher in eastern Europe than in central 
Europe or elsewhere. In central Asia, representative of the 
mixed levels of sociodemographic status present in the 
region, leading causes include neonatal encephalopathy 
and congenital causes. In central Latin America, violence, 
ischaemic heart disease, diabetes, low back and neck pain, 
and road injuries comprise the top ﬁ ve causes. Other 
examples of distinct regional patterns include the high 
ranking of COPD in east Asia, the dominance of malaria 
in west Africa, and the dominance of HIV/AIDS in eastern 
and southern sub-Saharan Africa. Within some regions, 
such as north Africa and the Middle East, the leading 
causes varied substantially.
Discussion
Global health is improving: life expectancy at birth rose 
by 6·2 years between 1990 and 2013, while HALE at birth 
increased by 5·4 years during the same interval; 
worldwide, age-standardised DALY rates fell by 27%. 
Global progress has accelerated since 2005 because of 
major reductions in HIV/AIDS and malaria, in addition 
to continued progress against other major communicable, 
maternal, neonatal, and nutritional disorders. Although 
the total volume of DALYs is down by only 3·6% over the 
23 year period, this is largely explained by population 
growth and ageing driving up numbers of DALYs. 
Declines in age-standardised DALY rates are 
counterbalanced by population growth and ageing, so 
that, despite improvements in age–sex-speciﬁ c health 
status, demands on health systems remain high. An 
example of these demands is the fact that the number of 
individuals in the world living in states of health 
characterised by a disability weight greater than 0·1 has 
increased by 43% from 1990 to 2013.
In 1971, Omran27 outlined the concept of the 
epidemiological transition to describe the changing pattern 
of causes of death that results from sociodemographic 
development. The notion of the epidemiological transition 
has been expanded to recognise the phase in transition 
that leads to double burden of disease9,28,29 and the 
countertransitions of the HIV/AIDS epidemic and the rise 
Figure 6: Ten most common GBD level 3 causes of DALYs for 188 countries in 2013
The 15 most common global causes of DALYs are coloured. Alcohol=alcohol use disorders. Alzheimer=Alzheimer’s disease and other dementias. Anxiety=anxiety disorders. Back and neck=low back and 
neck pain. Cirr Hep C=cirrhosis due to hepatitis C. CKD=chronic kidney disease. CMP=cardiomyopathy and myocarditis. Colorect C=colon and rectum cancer. Congenital=congenital disorders. 
COPD=chronic obstructive pulmonary disease. Depression=depressive disorders. Diabetes=diabetes mellitus. Diarrhoea=diarrhoeal diseases. Drown=drowning. Drugs=drug use disorders. 
F Body=foreign body. Haemog=haemoglobinopathies and haemolytic anaemias. HTN HD=hypertensive heart disease. IHD=ischaemic heart disease. Iron=iron-deﬁ ciency anaemia. Liver C=liver cancer. 
LRI=lower respiratory infections. Lung C=tracheal, bronchus, and lung cancer. Nematode=intestinal nematode infections. NN enceph=neonatal encephalopathy due to birth asphyxia and trauma. 
NN preterm=preterm birth complications. NN sepsis=neonatal sepsis and other neonatal infections. Other cardio=other cardiovascular and circulatory diseases. Other MSK=other musculoskeletal 
disorders. Other NN=other neonatal disorders. PEM=protein-energy malnutrition. Road inj=road injuries. Sense=sense organ diseases. Skin=skin and subcutaneous diseases. STD=sexually transmitted 
diseases excluding HIV. Stomach C=stomach cancer. Stroke=cerebrovascular disease. TB=tuberculosis. Violence=interpersonal violence. War=collective violence and legal intervention. 
DALY=disability-adjusted life-years. GBD=Global Burden of Disease.
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of mortality in the former Soviet Union.2,10,11,13,30–32 Many 
studies have recognised regional and national variation in 
the epidemiological transition.9,14,33–35 Taking advantage of 
the database of the GBD 2013 country-level results from 
1990 to 2013, we have quantiﬁ ed the extent to which 
sociodemographic status accounts for changes in 
epidemiological patterns, as opposed to other factors 
changing over time or static variation between countries. 
Isolation of this component of the variation of DALY rates 
allows examination of the shifts in disease and injury 
patterns that would be expected purely as a function of 
changing sociodemographic status. As sociodemographic 
status rises, YLLs from diarrhoea, lower respiratory 
infections, neonatal causes, maternal mortality, and other 
infectious causes decline substantially, while at the same 
time, there has been a slower rise in YLDs from 
musculoskeletal disorders, mental and substance use 
disorders, neurological disorders, and diabetes, urogenital, 
blood, and endocrine diseases. DALY rates for neoplasms 
and cardiovascular disease are minimally related to 
sociodemographic status; instead local factors have a 
profound eﬀ ect. However, with rising sociodemographic 
status, the proportion of DALYs due to these causes 
increases because of decreases in other causes of YLLs. 
Although, DALY rates for cardiovascular disease seem not 
to be related to sociodemographic status, large declines 
have been recorded for these causes in high-income 
countries in age-standardised rates over the past decades. 
The wide variation between some high sociodemographic 
status countries, such as Japan and Finland, shows how 
other factors, such as diet, physical activity, and other risks, 
vary substantially within the same level of 
sociodemographic status and also aﬀ ect cardiovascular 
disease outcomes. Furthermore, our analysis of the 
epidemiological transition is based on crude population 
rates, so reductions in age-speciﬁ c cardiovascular rates 
associated with rising sociodemographic status are 
countered by shifts towards an older population. Our 
analysis of the epidemiological transition shows decreases 
in DALY rates for cardiovascular disease at the very highest 
levels of sociodemographic status. Notably, the predictable 
rise in YLD rates for some causes (such as musculoskeletal 
disorders, diabetes mellitus, and mental and substance 
use disorders) driven by population ageing is not well 
recognised in the literature about the epidemiological 
transition.
Our decomposition of variance analysis shows that, for 
many NCDs, the main determinants of variation in 
DALY rates are country-speciﬁ c eﬀ ects, not the 
epidemiological transition. Global health can be 
understood in terms of a general theme in which change 
in epidemiological patterns is related to sociodemographic 
status, upon which country-speciﬁ c patterns are overlaid. 
Little of the variation in DALY rates was attributable to 
the year, which contrasted with previous ﬁ ndings 
showing that the association between life expectancy and 
income and education has shifted over time.24,36–38 Our 
analysis only covers a 23 year period, which might be too 
short to fully capture the eﬀ ects of changing 
sociodemographic status. Some of the country eﬀ ects, 
such as those noted for neglected tropical diseases and 
malaria, might have been related to sociodemographic 
status in a longer run analysis. The substantial eﬀ ect of 
country variation on the epidemiological transition 
pattern reinforces the importance of estimating the 
burden of disease for each country individually. The GBD 
results can be used productively in the future to 
characterise the deviation of individual countries from 
the general epidemiological transition. Our analysis of 
the association between crude DALY rates and country 
sociodemographic status does not provide insights into 
within-country disease associations across individual 
levels of socioeconomic status. For example, ﬁ ndings 
from multiple studies have shown that individuals of 
lower socioeconomic status have increased rates of 
cardiovascular and circulatory diseases.39–47
HALE varies widely between countries and over time. 
As a single summary measure of population health, 
HALE is fairly simple to explain and provides an indicator 
that is aﬀ ected by any changes in mortality rates or 
prevalence of disease or injury. HALE has been proposed 
as an indicator for the Sustainable Development Goals. 
As calculated through the GBD, HALE is an attractive 
measure that is sensitive to intervention and comparable 
over time and between populations. Although HALE 
needs input about the prevalence of multiple sequelae, 
the annual revisions of the GBD provide a widely available 
source for regular updates. By contrast, some other 
variants of health expectancies might be less appropriate 
for intertemporal or cross-country comparison. With 
measures that deﬁ ne disability according to arbitrary 
thresholds of disability weight, such as disability-free life 
expectancy (DFLE),48 even slight changes in the disability 
weight threshold will profoundly aﬀ ect conclusions about 
levels and changes in healthy life expectancy, as can be 
seen in ﬁ gure 1. Moreover, these measures are non-
standardised and hence not comparable: in some 
implementations of DFLE, the choice of the severity 
threshold to deﬁ ne disability is left to individual 
respondents in the surveys. For example, the European 
Union49 has adopted a measure of healthy life expectancy 
based on survey responses to a single item on activity 
limitations. Such a measure is susceptible to variation in 
the meaning attached to categorical descriptions of 
limitation levels, both between individuals and over time, 
as seen in related survey items on health status.50–52 An 
example of the sensitivity of DFLE measured in Europe is 
the reported decline in DFLE in Italy after 2004, which 
was caused by a change in question phrasing; we noted 
an increase in HALE for Italy in this study.53 Although 
HALE and DFLE both use disability weights, the 
continuous scale of disability weights used in HALE 
makes it less sensitive to measurement error than are the 
dichotomous (zero or one) weights used in DFLE.
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Our ﬁ ndings support those of Salomon and colleagues,8 
which showed that HALE is increasing more slowly than 
life expectancy: ie, as life expectancy increases, the 
expectation of years lived with multiple sequelae 
increases as well. The diﬀ erence between life expectancy 
and HALE has increased, whereas the ratio of this 
diﬀ erence to life expectancy has remained fairly constant. 
Whether or not this change should be termed an 
expansion of morbidity is not the issue. Rather, we saw 
that while health loss because of YLDs from 
cardiovascular and circulatory diseases and neoplasms 
might be decreasing, the real drivers of the diﬀ erence 
between HALE and life expectancy are musculoskeletal 
disorders, mental and substance use disorders, 
neurological disorders, and diabetes, along with vision 
loss and hearing loss. Prevalence for all of these 
conditions is strongly age-related, and age-standardised 
rates for them are not declining. Even though the age of 
onset for mental health and substance use disorders is 
not strongly age-related, the prevalence of these 
conditions tends to rise with age. Prevalence of 
musculoskeletal disorders, neurological disorders, 
diabetes, and hearing and vision loss rise even more 
profoundly with age. As individuals increasingly survive 
to 80 years and older, the amount of time spent with a 
combination of these disorders increases, even though 
age-standardised rates have not increased over time. 
According to our analysis, the available therapies have 
not led to signiﬁ cant declines in age-standardised YLD 
rates. Very few, if any, of these disorders receive the 
attention they deserve in public policy discourse about 
health and health research priorities.
Global health progress has been driven by impressive 
progress in reducing age-standardised rates for a wide 
range of causes of death. Age-standardised YLD rates, 
however, are not declining. Many potential reasons exist 
to explain the general success for mortality and absence 
of success for disease prevalence. Research and 
development investments by funders such as the US 
National Institutes of Health (NIH) and the 
pharmaceutical industry have focused on cardiovascular 
diseases, neoplasms, and endocrine disorders.54–59 As we 
report, in the early phases of the epidemiological 
transition, the major driver of change in disease and 
injury patterns is progress in the reduction of YLLs. We 
believe that the historical focus of health research 
funding on causes of YLLs was probably appropriate. 
However, health progress now means that more research 
investment is needed for the disorders that debilitate, 
rather than kill. With each passing year, the shift towards 
YLDs as the leading causes of disease burden will be 
more evident. Action is needed now to develop 
preventive, curative, and ameliorative strategies for 
these conditions rather than waiting until this shift is 
even more obvious.
Controlling for sociodemographic status, substantial 
variation exists for DALY rates between countries. In our 
decomposition of variance, the importance of 
intercountry variation ﬂ uctuated by cause; for example, 
country level variation explains little variation for 
neonatal causes, but most variation for self-harm and 
interpersonal violence. These ﬁ ndings raise the question 
of whether the division of countries into 21 regions in 
GBD based on geographic contiguity and the levels and 
patterns of adult and child mortality rates is the best way 
to explain the variance in DALY rates. With country-
speciﬁ c results now available, more sophisticated 
clustering methods could be used, with various 
constraints, to propose a more empirically calculated set 
of regions. Regions have two dimensions: analytical and 
presentational. The presentational dimension is easily 
addressed because results for any set of countries can 
easily be generated from the country-speciﬁ c results. In 
fact, the GBD Compare data visualisation tool provides 
several alternative presentational groupings, such as 
WHO political regions or World Bank regions. However, 
regions have an analytical eﬀ ect on the results if the 
super-region and region hierarchy have been used in the 
Bayesian modelling. In the GBD cause of death analysis, 
spatiotemporal Gaussian process regression models use 
the GBD hierarchy to borrow strength. In DisMod-MR 
2.0, the regional hierarchy also aﬀ ects estimation of the 
prior for each country analysis. More simply, where data 
are sparse or not available, the GBD regional groupings 
can have an important analytical eﬀ ect. More research is 
needed on two fronts. First, to explore the extent to which 
alternative regional groupings would explain more of the 
variance in the DALY results (or any other GBD 
indicator). Second, whether analytical tools, such as 
cause of death ensemble modelling (CODEm)60 or 
DisMod-MR 2.0,1 could be modiﬁ ed to easily allow for 
diﬀ erent regional hierarchies for diﬀ erent causes.
This study has all the limitations previously reported 
for the GBD 2013 analysis of YLLs and YLDs.1,2 
Additionally, a key limitation is the assumption that 
uncertainty is independent for YLLs and YLDs. In fact, 
for diseases modelled with DisMod-MR 2.0, we 
estimated a correlation between the uncertainty in 
condition-speciﬁ c mortality and the uncertainty in 
prevalence. However, DisMod-MR 2.0 estimates excess 
mortality related to a cause, not the mortality that would 
be assigned to a cause according to the ICD principles of 
underlying cause. In future iterations of the GBD, it 
might be useful to attempt to use the correlation 
structure produced from DisMod-MR 2.0 as a proxy for 
the correlation between the underlying cause and 
prevalence. By assuming independence, we might be 
underestimating overall uncertainty in DALYs. However, 
more careful examination of the uncertainty in YLDs 
reveals that most uncertainty stems from uncertainty in 
disability weights and not from uncertainty in 
prevalence. We have no reason to assume that the 
uncertainty associated with valuations of health states in 
population surveys would be correlated with either 
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disease or death outcomes. Inclusion of the smaller 
component of the correlation of prevalence with 
mortality in the estimation of DALY uncertainty would 
probably not substantially alter the large uncertainty 
already recorded for DALYs. Another key limitation, is 
that our assessment of the burden of disease related to 
sociodemographic status was aﬀ ected by the choice of 
variables that we have included in our sociodemographic 
status indicator (income per person, average years of 
schooling after age 15 years, total fertility rate, and mean 
age of the population). Alternative measures of 
sociodemographic status could be developed that might 
explain more of the variance seen for some GBD level 2 
causes of DALYs. However, we experimented with 
alternative formulations, including the addition of 
urbanisation and all combinations of the four variables 
in our index, and established that the approach we used 
had the most explanatory power. Other variables that 
would be interesting to include in a composite country-
level sociodemographic status measure, such as the Gini 
coeﬃ  cient, were not available for all countries in all 
years. Notably, where both measures are available, the 
correlation between the sociodemographic status 
indicator and the UN Human Development Index 
during the 23 year time period was 0·95.
In the post-Millennium Development Goal (MDG) era, 
there is much interest in identiﬁ cation of appropriate 
goals for population health and how these goals should 
be monitored.4 Increasingly, measurement frameworks 
to assess levels of health in populations have moved away 
from measures of survival to encompass more holistic 
measures of disability as well as mortality. Our ﬁ ndings 
suggest that this broader focus is probably going to be 
increasingly relevant to guide countries’ public policy 
interventions. Large, impressive, and sustained gains are 
being made against the majority of leading causes of 
death in most countries, but as our ﬁ ndings show, these 
gains are not being accompanied by commensurate 
declines in age-standardised rates of disability, especially 
from major musculoskeletal disorders, mental and 
substance use disorders, neurological disorders, and 
diabetes. Moreover, the failure of health information 
systems to reliably describe trends in these disorders not 
only severely hampers policy responses, but contributes 
greatly to their further neglect and insuﬃ  cient awareness 
of the signiﬁ cant part they now play in overall population 
health. Despite the important country variation in 
measures of population, now is the time for the global 
health community, donors and countries alike, to 
maximise the opportunities for health that have resulted 
from the data revolution, and ensure that priority is given 
to the development of scientiﬁ cally valid, feasible, and 
informative data systems to measure progress in 
reducing disability. Improved data and monitoring can 
help decision makers to reduce DALYs from a wide range 
of causes by pursuing the most important opportunities 
for prevention, treatment, and rehabilitation.
For the United Nations 
Development Programme 
Human Development Index see 
http://hdr.undp.org/en/content/
human-development-index-hdi
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